Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?

J Acquir Immune Defic Syndr. 2007 May 1;45(1):123-5. doi: 10.1097/QAI.0b013e318040b2b6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • Bilirubin / blood
  • Chi-Square Distribution
  • Dideoxynucleosides / therapeutic use*
  • Drug Interactions
  • Drug Therapy, Combination
  • HIV
  • HIV Infections / blood
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • Hepatitis C / blood
  • Hepatitis C / complications*
  • Hepatitis C / drug therapy*
  • Hepatitis C / therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Multivariate Analysis
  • RNA, Viral / blood
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins
  • Ribavirin / therapeutic use*
  • Time Factors
  • Treatment Failure
  • Viral Load

Substances

  • Anti-HIV Agents
  • Antiviral Agents
  • Dideoxynucleosides
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Ribavirin
  • Bilirubin
  • abacavir